PharMerica Corp. (NYSE:PMC) shares saw an uptick in trading volume on Tuesday . 366,567 shares traded hands during trading, an increase of 116% from the previous session’s volume of 169,644 shares.The stock last traded at $24.52 and had previously closed at $26.27.

A number of brokerages have issued reports on PMC. Zacks Investment Research lowered shares of PharMerica Corp. from a “hold” rating to a “sell” rating in a research note on Thursday. Bank of America Corp. began coverage on shares of PharMerica Corp. in a report on Tuesday, June 7th. They set a “buy” rating and a $32.00 price target on the stock. TheStreet downgraded shares of PharMerica Corp. from a “buy” rating to a “hold” rating in a report on Monday, May 9th. Finally, Barrington Research restated an “outperform” rating and set a $34.00 price target (up previously from $30.00) on shares of PharMerica Corp. in a report on Tuesday, May 10th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $31.57.

The stock has a 50-day moving average of $25.53 and a 200-day moving average of $25.10. The company has a market cap of $686.29 million and a P/E ratio of 23.26.

PharMerica Corp. (NYSE:PMC) last released its quarterly earnings results on Tuesday, August 9th. The company reported $0.47 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.47. The company earned $519.60 million during the quarter, compared to analyst estimates of $508.31 million. During the same quarter last year, the company earned $0.48 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Analysts forecast that PharMerica Corp. will post $2.01 earnings per share for the current year.

A number of hedge funds and institutional investors have made changes to their positions in PMC. Russell Frank Co boosted its position in shares of PharMerica Corp. by 8.3% in the fourth quarter. Russell Frank Co now owns 29,018 shares of the company’s stock valued at $1,016,000 after buying an additional 2,213 shares during the last quarter. Trexquant Investment LP boosted its position in shares of PharMerica Corp. by 148.9% in the fourth quarter. Trexquant Investment LP now owns 30,140 shares of the company’s stock valued at $1,055,000 after buying an additional 18,031 shares during the last quarter. Redwood Investments LLC boosted its position in shares of PharMerica Corp. by 6.3% in the fourth quarter. Redwood Investments LLC now owns 58,400 shares of the company’s stock valued at $2,044,000 after buying an additional 3,444 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of PharMerica Corp. by 3.8% in the fourth quarter. California Public Employees Retirement System now owns 111,808 shares of the company’s stock valued at $3,913,000 after buying an additional 4,100 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of PharMerica Corp. by 42.6% in the fourth quarter. New York State Common Retirement Fund now owns 156,103 shares of the company’s stock valued at $5,464,000 after buying an additional 46,660 shares during the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.